CMX-2043

DB12795InvestigationalSmall molecule

CMX-2043 has been used in trials studying the treatment and prevention of Non STEMI, Unstable Angina, Stable Coronary Artery Disease, and Percutaneous Coronary Intervention.

Formula / weight: C₁₆H₂₆N₂O₆S₂ · 406.51 g/mol (avg)
Code names: CMX-2043

Resolves to

Compound

UNII83V80O4XY1CAS910627-26-8ChEMBLCHEMBL3099551PubChem49802864

Structure

InChIKeyMQXRTCVZPIHBLD-TUAOUCFPSA-NSMILESC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)CCCC[C@@H]1CCSS1)C(O)=O

Targets

P08581METP31749AKT1

What you can answer from here — as of April 02, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with CMX-2043, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account